

Part VI: Summary of the risk management plan

Summary of risk management plan for ENALAPRIL/LERCANIDIPINE

This is a summary of the Risk Management Plan (RMP) for enalapril/lercanidipine. The RMP details important risks of enalapril/lercanidipine, how these risks can be minimised, and how more information will be obtained about enalapril/lercanidipine 's risks and uncertainties (missing information).

Enalapril/lercanidipine's Summary of Product Characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how enalapril/lercanidipine should be used.

Important new concerns or changes to the current ones will be included in updates of enalapril/lercanidipine's RMP.

I. The medicine and what it is used for

Enalapril/lercanidipine, is authorized for:

-Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by lercanidipine 10 mg alone.

-Treatment of essential hypertension in patients whose blood pressure is not adequately controlled by enalapril 20 mg alone.

Fixed combination enalapril/lercanidipine 20mg/10mg should not be used for initial treatment of hypertension.

A line-extension for the dosage 20 mg/20 mg is under application with the proposed indication:

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled with enalapril 20 mg and lercanidipine 20 mg given concurrently as separate tablets.

It contains enalapril/lercanidipine as the active substance and it is given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of enalapril/lercanidipine, together with measures to minimise such risks and the proposed studies for learning more about enalapril/lercanidipine 's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of enalapril/lercanidipine are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of enalapril/lercanidipine. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

| Summary of safety concerns | |
|----------------------------|--|
| Important identified risks | <ul style="list-style-type: none">• None |
| Important potential risks | <ul style="list-style-type: none">• None |
| Missing information | <ul style="list-style-type: none">• None |

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of products containing enalapril and lercanidipine covered by this RMP.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for products containing enalapril and lercanidipine covered by this RMP.